ArticlePLOS global public health2026
Enhancing Hepatitis B case finding through tech-enhanced community pharmacy: Results from a trial program in Vietnam.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) remains a major public health challenge in Vietnam. Barriers include limited awareness and access to screening as well as out-of-pocket diagnosis and treatment costs. Point-of-care rapid diagnostic tests (RDTs) offer an opportunity to expand screening and linkages to diagnosis and care. This intervention assessed technology-enhanced community pharmacies ability to provide HBV screening and find cases in Vietnam using digital monitoring and cross-sectional digital survey data. Between February 2024 and March 2025, SwipeRx partnered with the Vietnamese Pharmaceutical Association and the commercial supplier of Determine HBsAg-RDT to implement a trial program including digital campaigns, accredited digital training, in-pharmacy and mobile coaching, and supplier linkages. Monitoring and cross-sectional digital survey data were used to assess changes in HBV knowledge and practices at the pharmacy. Among 917 pharmacists who completed the accredited online training, 117 pharmacies with at least 1 trained pharmacist received coaching and procured 5,900 HBsAg-RDTs, with 48% placing repeat orders. During the same six-month period, 84% (98/117) of pharmacies identified 270 pharmacy clients who tested positive out of 2,840 unique clients screened using HBsAg-RDT prior to referral to a nearby health facility for confirmatory HBV diagnosis. Pharmacists who completed the digital training and were engaged with digital campaigns and coaching were 2.83 times more likely to stock HBsAg-RDT and reported significantly higher HBV-related knowledge and confidence compared to non-engaged pharmacists. This research demonstrates how technology-enabled training and pharmacy engagement can facilitate community access to new health products and services, including HBV screening. Optimizing test packaging, pricing, and pharmacy client demand may further expand access to and uptake of HBV screening through community pharmacies in future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.